Glaxosmithkline | GSK - Gross Profit On Sales


Glaxosmithkline reported GBP5.75B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
AstraZeneca USD 12.86B 251M Jun/2026
Aurora Cannabis CAD 29.79M 16.83M Mar/2026
Bausch Health Companies USD 2.08B 294M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Canopy Growth CAD 8.26M 13.2M Mar/2026
Corcept Therapeutics USD 252.09M 90.07M Jun/2026
Drreddys Laboratories INR 43.04B 3.77B Mar/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Glaxosmithkline GBP 5.75B 2.99B Mar/2026
J&J USD 18.55B 1.31B Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Pacira USD 133.91M 7.27M Jun/2026
Perrigo USD 313.9M 11.6M Jun/2026
Pfizer USD -248M 11.29B Jun/2026
Phibro Animal Health USD 133.5M 12.6M Dec/2025
Prestige Brands USD 136.19M 10.11M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sanofi EUR 8.71B 602M Jun/2026
Supernus Pharmaceuticals USD 160.06M 30.7M Jun/2026
Takeda JPY 813.22B 124.39B Jun/2026
Teva Pharmaceutical Industries USD 2.15B 45M Jun/2026
Zoetis USD 1.76B 140M Jun/2026